联系方式：400-650-8506
CNEN
产品名称 BAY 57-1293 - Pritelivir | AIC 316
产品货号 Axon 2266 CAS [348086-71-5] MF C18H18N4O3S2MW 402.49 Purity: 99% Soluble in DMSO Description Potent helicase-primase inhibitor (HPI) effective against herpes simplex virus (HSV) infections with IC50 value of 20 nM for inhibition of the replication of both HSV-1 and HSV-2 in Vero cells, and ED50 value of 0.5 mg/kg for both HSV-1 and HSV-2 in the murine lethal challenge model of disseminated herpes. BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections, and is active also against acyclovir-resistant mutant strains which carry mutations in the tk or DNA pol genes. References Certificates Categories Extra info J.J. Crute et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 2002, 8, 386-391.   U.A. Betz et al. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 2002, 46, 1766-1772.   S. Biswas et al. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 2007, 75, 30-35. Certificate of Analysis Material Safety Data Sheet Immunology Helicase-Primase EC 3.6.4.12 Potent helicase-primase inhibitor, effective against herpes simplex virus (HSV) infections Chemical name N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide Parent CAS No. [348086-71-5] Order Size Unit Price Stock 5 mg €80.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

BAY 57-1293 - Pritelivir | AIC 316

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 2266

CAS [348086-71-5]

MF C18H18N4O3S2
MW 402.49

  • Purity: 99%
  • Soluble in DMSO

BAY 57-1293

Description

Potent helicase-primase inhibitor (HPI) effective against herpes simplex virus (HSV) infections with IC50 value of 20 nM for inhibition of the replication of both HSV-1 and HSV-2 in Vero cells, and ED50 value of 0.5 mg/kg for both HSV-1 and HSV-2 in the murine lethal challenge model of disseminated herpes. BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections, and is active also against acyclovir-resistant mutant strains which carry mutations in the tk or DNA pol genes.
产品资料